Active — Not RecruitingNot Applicable

Hydroxychloroquine May be Beneficial for Preeclampsia

China462 participantsStarted 2024-01-01

Plain-language summary

The purpose of this research is to investigate the impact of hydroxychloroquine on the incidence of hypertensive pregnancy disorders in women with a history of recurrent spontaneous abortion (RSA).

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. singleton pregnant women
✓. with a history of two or more miscarriages

Exclusion criteria

✕. indication to a treatment according to the severe cardiovascular, immune, respiratory, gastrointestinal/liver and biliary system, kidney and urinary system, nervous system, musculoskeletal system, psychiatric, infectious disease, malignancy,
✕. major malformation of the fetus diagnosed at 11-13 weeks of gestation.
✕. Known paternal, maternal, or embryo chromosome abnormality;
✕. Abnormal uterine anatomy at hysterosalpingography/hysteroscopy or hydrosonography that might explain RM in the first trimester of pregnancy;
✕. Maternal endocrine dysfunction: premature ovarian failure, hyperprolactinemia, corpus luteal insufficiency, untreated diabetes mellitus or untreated thyroid dysfunction.

What they're measuring

Composite morbidity

Timeframe: Gestational period

Trial details

NCT IDNCT06020378

SponsorRenJi Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-07-01

View on ClinicalTrials.gov More Pre-Eclampsia trials